BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roncero C, Villegas JL, Martínez-Rebollar M, Buti M. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Rev Clin Pharmacol 2018;11:999-1030. [PMID: 30199279 DOI: 10.1080/17512433.2018.1519392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Zhang K, Zhou X, Liu H, Hashimoto K. Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders. Br J Psychiatry 2020;217:351. [PMID: 32270760 DOI: 10.1192/bjp.2020.84] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
2 Marcos-Fosch C, Cabezas J, Crespo J, Buti M. Anti-epileptic drugs and hepatitis C therapy: Real-world experience. J Hepatol 2021;75:984-5. [PMID: 34126106 DOI: 10.1016/j.jhep.2021.05.040] [Reference Citation Analysis]
3 Sicras Mainar A, Navarro Artieda R, Hernández I, Morillo R. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. Gastroenterol Hepatol 2019;42:465-75. [PMID: 31451229 DOI: 10.1016/j.gastrohep.2019.03.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
4 Li YP, Yang Y, Wang MQ, Zhang X, Wang WJ, Li M, Wu FP, Dang SS. Facial and bilateral lower extremity edema due to drug-drug interactions in a patient with hepatitis C virus infection and benign prostate hypertrophy: A case report. World J Clin Cases 2020; 8(15): 3372-3376 [PMID: 32874995 DOI: 10.12998/wjcc.v8.i15.3372] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. Visc Med. 2019;35:161-170. [PMID: 31367613 DOI: 10.1159/000500963] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
6 Machado SM, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D, Tenore SB, Brandão-Mello CE, Gonzalez MP, Siroma F, Prado KD, Nunes DV, Lisboa-Neto G, Pinho JRR, Malta FM, Azevedo RS, Witkin SS, Mendes-Correa MC. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine (Baltimore) 2020;99:e21270. [PMID: 32791706 DOI: 10.1097/MD.0000000000021270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Mangia A, Scaglione F, Toniutto P, Pirisi M, Coppola N, Di Perri G, Alvarez Nieto G, Calabrese S, Hernandez C, Perrone V, Degli Esposti L, Fagiuoli S. Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. Int J Environ Res Public Health 2021;18:7144. [PMID: 34281080 DOI: 10.3390/ijerph18137144] [Reference Citation Analysis]
8 Natali KM, Jimenez HR, Slim J. When Coadministration Cannot Be Avoided: Real World Experience of Direct Acting Antivirals for the Treatment of Hepatitis C Virus Infection in Patients on First Generation Anticonvulsants. J Pharm Pract 2020;:897190020977762. [PMID: 33317381 DOI: 10.1177/0897190020977762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Spina E, Barbieri MA, Cicala G, de Leon J. Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents. Pharmaceuticals (Basel) 2020;13:E439. [PMID: 33276675 DOI: 10.3390/ph13120439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Boff da Costa R, Boff Costa M, Longo L, Miotto DE, Hirata Dellavia G, Trucollo Michalczuk M, Reis Álvares-da-Silva M. Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications. PLoS One 2021;16:e0245767. [PMID: 33577593 DOI: 10.1371/journal.pone.0245767] [Reference Citation Analysis]
11 Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrob Agents Chemother 2019:AAC. [PMID: 31591118 DOI: 10.1128/AAC.01215-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
12 Roncero C, Vicente-Hernández B, Casado-Espada NM, Aguilar L, Gamonal-Limcaoco S, Garzón MA, Martínez-González F, Llanes-Álvarez C, Martínez R, Franco-Martín M, Álvarez-Navares A. The Impact of COVID-19 Pandemic on the Castile and Leon Addiction Treatment Network: A Real-Word Experience. Front Psychiatry 2020;11:575755. [PMID: 33324254 DOI: 10.3389/fpsyt.2020.575755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Sicras-Mainar A, Morillo-Verdugo R. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. J Int Med Res 2020;48:300060520964659. [PMID: 33111612 DOI: 10.1177/0300060520964659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]